Background: Previous studies suggest that group therapies, including acceptance and commitment therapy (ACT) and logotherapy, successfully reduce stress in patients. Objectives: The present study aimed to compare the effectiveness of acceptance and commitment group therapy and group logotherapy in reducing perceived stress among multiple sclerosis (MS) patients. Materials and Methods: This re...

Multiple Sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system that may lead to disability of the patient. Current MS treatment regimens are still insufficient and research is conducted for developing more effective therapies capable of targeting neurodegeneration, inflammation, and demyelination. Recent results of experimental and clinical studies in ...

BACKGROUND AND PURPOSE Mitoxantrone is an approved disease modifying agent for treatment of multiple sclerosis (MS). The aim of the study was to assess its efficacy and safety in Indian MS patients. MATERIALS AND METHODS A total of 23 patients with clinically definite MS (Poser criteria) were enrolled in an open label study. Of which, 21 satisfied the McDonald's criteria for MS and two satisf...

Objectives: Mental practice, as a neuropsychological factor effective in motor recovery, is a cognitive rehearsal of a physical skill without muscular activity. Considering the high level of fatigue in patients with Multiple Sclerosis (MS), we hypothesized that using mental practice as a low-level energy-consuming method added to physical practice could be a useful therapeutic strategy. Therefo...

Despite the various therapies available, the use of monoclonal antibodies is a highly specific approach that has only recently been of interest to researchers. The properties of antibodies have led to their use in the treatment of various diseases, including cancer, Alzheimer's disease, diabetes and multiple sclerosis (MS). MS, a chronic inflammatory disease, occurs commonly in young adults. Th...

Neuronal growth factors may exert a neuroprotective effect in multiple sclerosis (MS). We found reduced levels of brain-derived neurotrophic factors (BDNF) in the serum and CSF of relapsing-remitting MS patients, which was reversed by therapy with glatiramer acetate. BDNF may play a protective role in MS, and immunomodulation therapy, such as with glatiramer acetate, may enhance the action this...

Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory, demyelinating disease of the central nervous system. MS is increasingly recognized in the pediatric population, and it is usually diagnosed around 15 years of age. The exact etiology of MS is still not known, although autoimmune, genetic, and environmental factors play important roles in its development, making it a multifactorial ...

Autoimmune T and B cell responses to CNS antigen(s) are thought to drive the pathogenesis of multiple sclerosis (MS), and thus are logical targets for therapy. Indeed, several immunomodulatory agents, including IFN-beta 1b, IFN-beta 1a, glatiramer acetate, and mitoxantrone, have had beneficial clinical effects in different forms of MS. However, because the available treatments are only partiall...